CXCR2 and chronic obstructive pulmonary disease: The promising profile of AZD5069, a CXCR2 inhibitor, in a chronic obstructive pulmonary disease (COPD) model was not replicated in asthma either, with only a decrease in neutrophil counts in patients' sputum but no improvement in overall clinical outcome [41].